Literature DB >> 21670746

Peripheral artery disease. Part 2: medical and endovascular treatment.

Mitchell D Weinberg1, Joe F Lau, Kenneth Rosenfield, Jeffrey W Olin.   

Abstract

The treatment of peripheral artery disease (PAD) focuses on risk factor modification, cardiovascular event reduction, limb viability, and symptom improvement. Hypertension, hyperlipidemia, and diabetes mellitus should all be controlled to recommended target levels, and smoking cessation is vital. Antiplatelet therapies, such as aspirin or clopidogrel, should be administered in all patients unless contraindicated. Whenever possible, patients who present with claudication should be offered a regimen comprised of both medical and exercise therapy, which often results in substantial improvement in symptoms. For patients presenting with more-advanced disease, such as acute limb ischemia, critical limb ischemia, and severely-limiting symptoms of PAD, revascularization is often necessary. As a result of the rapid evolution in endovascular revascularization technology and expertise, many patients with PAD can be treated percutaneously. Therefore, in this Review, we will focus on medical therapy and endovascular revascularization of patients with PAD, with reference to surgical bypass in specific clinical scenarios.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670746     DOI: 10.1038/nrcardio.2011.81

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  124 in total

1.  An economic appraisal of lower extremity bypass graft maintenance.

Authors:  C L Wixon; J L Mills; A Westerband; J D Hughes; D M Ihnat
Journal:  J Vasc Surg       Date:  2000-07       Impact factor: 4.268

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

Review 4.  Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication.

Authors:  B L W Bendermacher; E M Willigendael; J A W Teijink; M H Prins
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

5.  Intraarterial pressure gradients after randomized angioplasty or stenting of iliac artery lesions. Dutch Iliac Stent Trial Study Group.

Authors:  E Tetteroo; C Haaring; Y van der Graaf; J P van Schaik; A D van Engelen; W P Mali
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Nov-Dec       Impact factor: 2.740

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  Percutaneous intervention for infrainguinal occlusive disease in women: equivalent outcomes despite increased severity of disease compared with men.

Authors:  Brian G DeRubertis; Angela Vouyouka; Soo J Rhee; Joseph Califano; John Karwowski; Niren Angle; Peter L Faries; K Craig Kent
Journal:  J Vasc Surg       Date:  2008-07       Impact factor: 4.268

8.  Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.

Authors:  Jeffrey S Berger; Mori J Krantz; John M Kittelson; William R Hiatt
Journal:  JAMA       Date:  2009-05-13       Impact factor: 56.272

9.  Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.

Authors:  Yoshimitsu Soga; Hiroyoshi Yokoi; Tomohiro Kawasaki; Hitoshi Nakashima; Masanori Tsurugida; Yutaka Hikichi; Masakiyo Nobuyoshi
Journal:  J Am Coll Cardiol       Date:  2009-01-06       Impact factor: 24.094

10.  Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS).

Authors:  D Bergqvist; B Almgren; J P Dickinson
Journal:  Eur J Vasc Endovasc Surg       Date:  1995-07       Impact factor: 7.069

View more
  15 in total

1.  O(2) regulates skeletal muscle progenitor differentiation through phosphatidylinositol 3-kinase/AKT signaling.

Authors:  Amar J Majmundar; Nicolas Skuli; Rickson C Mesquita; Meeri N Kim; Arjun G Yodh; Michelle Nguyen-McCarty; M Celeste Simon
Journal:  Mol Cell Biol       Date:  2011-10-17       Impact factor: 4.272

2.  Multimodality imaging approach for serial assessment of regional changes in lower extremity arteriogenesis and tissue perfusion in a porcine model of peripheral arterial disease.

Authors:  Mitchel R Stacy; Da Yu Yu; Mark W Maxfield; Irina M Jaba; Bartosz P Jozwik; Zhen W Zhuang; Ben A Lin; Christi L Hawley; Christopher M Caracciolo; Prasanta Pal; Daniela Tirziu; Smita Sampath; Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2013-10-29       Impact factor: 7.792

Review 3.  Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis.

Authors:  Joe F Lau; Mitchell D Weinberg; Jeffrey W Olin
Journal:  Nat Rev Cardiol       Date:  2011-05-31       Impact factor: 32.419

4.  Computational Network Model Prediction of Hemodynamic Alterations Due to Arteriolar Rarefaction and Estimation of Skeletal Muscle Perfusion in Peripheral Arterial Disease.

Authors:  Joshua L Heuslein; Xuanyue Li; Kelsey P Murrell; Brian H Annex; Shayn M Peirce; Richard J Price
Journal:  Microcirculation       Date:  2015-07       Impact factor: 2.628

5.  Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes.

Authors:  Subhamoy Das; Anthony J Monteforte; Gunjan Singh; Marjan Majid; Michael B Sherman; Andrew K Dunn; Aaron B Baker
Journal:  Adv Healthc Mater       Date:  2016-02-18       Impact factor: 9.933

6.  Hypoxia-induced angiogenesis: good and evil.

Authors:  Bryan L Krock; Nicolas Skuli; M Celeste Simon
Journal:  Genes Cancer       Date:  2011-12

7.  Nanomedical Theranostics in Cardiovascular Disease.

Authors:  Jun Tang; Mark E Lobatto; Joanna C Read; Aneta J Mieszawska; Zahi A Fayad; Willem J M Mulder
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-11-29

8.  Fucoidan Stimulates Monocyte Migration via ERK/p38 Signaling Pathways and MMP9 Secretion.

Authors:  Elene Sapharikas; Anna Lokajczyk; Anne-Marie Fischer; Catherine Boisson-Vidal
Journal:  Mar Drugs       Date:  2015-06-30       Impact factor: 5.118

Review 9.  Vitamin D: Not Just Bone Metabolism but a Key Player in Cardiovascular Diseases.

Authors:  Marcello Izzo; Albino Carrizzo; Carmine Izzo; Enrico Cappello; Domenico Cecere; Michele Ciccarelli; Patrizia Iannece; Antonio Damato; Carmine Vecchione; Francesco Pompeo
Journal:  Life (Basel)       Date:  2021-05-18

10.  MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1.

Authors:  Anagha Sen; Shumei Ren; Carolin Lerchenmüller; Jianxin Sun; Norbert Weiss; Patrick Most; Karsten Peppel
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.